BERLIN & NEVADA--(BUSINESS WIRE)--MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today published its second Shareholder Letter 2015: "Dear MagForce Shareholders, I am pleased to report that we continue to make progress toward achieving our 2015 targets. Brain Cancer NanoTherm(TM) Therapy at MagForce AG Installation of additional NanoActivator(R) devices in Germany to treat Brain Cancer: